mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== History == Buprenorphine was first synthesised from thebaine in 1966. In 1969, researchers at Reckitt and Colman (now Reckitt Benckiser) had spent 10 years attempting to synthesize an opioid compound "with structures substantially more complex than morphine [that] could retain the desirable actions whilst shedding the undesirable side effects". Physical dependence and withdrawal from buprenorphine itself remain important issues since buprenorphine is a long-acting opioid. Reckitt found success when researchers synthesized RX6029 which had shown success in reducing dependence in test animals. RX6029 was named buprenorphine and began trials on humans in 1971. Buprenorphine was approved for use in humans in 1977 in the UK and 1982 in the US. Buprenorphine was first used in dogs in the 1980s and in cats in the 1990s. A 0.3mg/ml formulation for use in cats was approved in 1995, a higher strength 1.8mg/ml formulation was approved in 2014, and a transdermal patch was approved in 2022.
=== Regulation === Methaqualone was initially placed in Schedule I as defined by the UN Convention on Psychotropic Substances, but was moved to Schedule II in 1979. In Canada, methaqualone is listed in Schedule III of the Controlled Drugs and Substances Act and requires a prescription, but it is no longer manufactured. Methaqualone is banned in India. In the United States it was withdrawn from the market in 1983 and made a Schedule I drug in 1984.
=== 2004—2008: Third Michelin star and international acclaim === In 2004, the Fat Duck became the third restaurant in the UK to receive three Michelin stars, after the Waterside Inn, also in Bray, and Restaurant Gordon Ramsay in London. It was the fastest that a British restaurant had gone from one to three stars. At the time he received his third star, Blumenthal said it was the closest he had been to bankruptcy, with enough money only to cover the following week's staff wages. Immediately after receiving the third star, the Fat Duck began receiving hundreds of phone calls seeking reservations a day. Blumenthal hired Tony Baker as managing director to help deal with the demand. In the same year, the Fat Duck was ranked second in the world behind the French Laundry by the World's 50 Best Restaurants. It also received the title of Square Meal BMW Best UK Restaurant 2004. That year, food and safety officers found "borderline" levels of listeria in the foie gras and expressed concern that "no core temperatures of the meat are taken". The Daily Telegraph reported that the Fat Duck dealt with the problem and introduced "stringent procedures." In 2005, the World's 50 Best Restaurants named the Fat Duck the best restaurant in the world. At the first Front of House Awards in 2007, it won the awards for Overall Service and Front Desk of the Year. As of 2007, the Fat Duck employed 32 chefs, with a weekly wage bill of around £35,000. It seated 46 people for lunch and dinner six days a week, with an average spend of around £175 per head and an annual turnover of more than £4 million.
Sources: en.wikipedia.org
Francium can be synthesized by a fusion reaction when a gold-197 target is bombarded with a beam of oxygen-18 atoms from a linear accelerator in a process originally developed at the physics department of the State University of New York at Stony Brook in 1995. Depending on the energy of the oxygen beam, the reaction can yield francium isotopes with masses of 209, 210, and 211.
== Production and occurrence == Pentane is produced by fractional distillation of petroleum and purified by rectification (successive distillations). It occurs in alcoholic beverages and in hop oil. It is a component of exhaled breath for some individuals. A degradation product of unsaturated fatty acids, its presence is associated with some diseases and cancers. Pentane is a relatively minor component of automobile gasoline, with its share varying within 1–6% in 1990s Sweden, 2–13% in 1990s US and 1–3% in the US in 2011. At 62, its octane number (both RON and MON) is quite low.
In the mid-1980s to 1990s, Singaporeans could also use the locally based videotext service Singapore Teleview to communicate with one another. The phrase Intelligent Island arose in the 1990s in reference to the island nation's early adaptive relationship with the internet. In 2016, there were an estimated 4.7 million internet users in Singapore, representing 82.5% of the population. The Singapore government does not engage in widespread censoring of the internet, but it maintains a list of one hundred websites—mostly pornographic—that it blocks from home internet access as a "symbolic statement of the Singaporean community's stand on harmful and undesirable content on the Internet". Singapore has the world's highest smartphone penetration rates, in surveys by Deloitte and the Google Consumer Barometer—at 89% and 85% of the population respectively in 2014. The overall mobile phone penetration rate is at 148 mobile phone subscribers per 100 people.
At times, the mucous membrane around the uvula may swell, causing the uvula to expand 3–5 times its normal size. This condition is known as uvulitis. When the uvula touches the throat or tongue, it can cause sensations like gagging or choking, although there is no foreign matter present. This can cause problems with breathing, talking, and eating. There are many theories about what causes the uvula to swell, including dehydration (e.g. from arid weather); excessive smoking or other inhaled irritants; snoring; allergic reaction; or a viral or bacterial infection. An aphthous ulcer which has formed on the uvula can also cause swelling and discomfort. If the swelling is caused by dehydration, drinking fluids may improve the condition. If the cause is a bacterial infection, gargling salt water may help. However, it can also be a sign of other problems. Some people with a history of recurring uvulitis carry an epinephrine autoinjector to counteract symptoms of an attack. A swollen uvula is not normally life-threatening and subsides in a short time, typically within a day.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.